Conference Call with Granules India Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Granules India announced Q4FY23 results: Revenue from operations of Q4FY23 stood at Rs 11,955 million, a growth of 16% YoY, primarily driven by higher sales in key geographies, including the US and Europe. Revenue share from the USA increased to 54% in Q4FY23 as compared to 48% YoY. Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and finished dosages contribute 31%, 18%, and 51% of revenue from operations respectively for Q4FY23. RoCE increased to 21.1% as compared to 19.3% YoY Net debt stood at Rs 7,671 million and Net debt to EBITDA at 0.84x Commenting on the results, Dr Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India said, “We have grown in terms of revenues year on year as well as sequential quarter despite the price erosion challenges in our key geographies including the US. Our Cash flow from operations has improved significantly this year as compared to FY22. This shows the strength of our business and will also help us fund our green initiatives in the coming quarters and years. We are moving towards a more sustainability-driven approach in the future and all our efforts and plans are geared towards that.” Result PDF